Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled, crossover study

Neurology

Volumn 49, Issue 6, 1997, Pages 1485-1490

  Mathew, Ninan T ^b   Asgharnejad, Mahnaz ^a   Peykamian, Margaret ^a   Laurenza, Antonio ^a  

^a Glaxco Wellcome ^*  (United States)

^b Houston Headache Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TINGLING; VOMITING;

EID: 0031454716     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.6.1485     Document Type: Article

References (16)

1. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
2. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265: 2831-2835.
3. The Oral Sumatriptan Dose-Defining Group. Sumatriptan: an oral, dose-defining study. Eur Neurol 1991;31:300-305.
4. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-313.
5. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991;338:782-783.
6. Dahlof CGH. How dose sumatriptan perform in clinical practice? Cephalalgia 1995;(suppl 15):21-28.
7. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994;14:330-338.
8. Visser WH, Terwindt GM, Reines AS, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996;53:1132-1137.
9. Geraud GEA. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Eur Neurol 1996; 36(suppl 2):24-27.
10. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-322.
11. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-152.
12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
13. Robson DS. A simple method for constructing orthogonal polynomials when the independent variable is unequally spaced. Biometrics 1959;15:187-191.
14. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995;45(suppl 7): 5-9.
15. Nappi G, Sicuteri F, Byrne M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138-144.
16. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996;36(suppl 2):4-7.